CVS Health Corporation $CVS Shares Purchased by Nvwm LLC

Nvwm LLC lifted its holdings in CVS Health Corporation (NYSE:CVS) by 12,778.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,697 shares of the pharmacy operator’s stock after acquiring an additional 6,645 shares during the period. Nvwm LLC’s holdings in CVS Health were worth $574,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Kilter Group LLC bought a new stake in CVS Health in the second quarter worth approximately $27,000. Sankala Group LLC bought a new position in shares of CVS Health during the 4th quarter worth approximately $28,000. Global Trust Asset Management LLC boosted its holdings in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 300 shares in the last quarter. J.Safra Asset Management Corp acquired a new stake in shares of CVS Health during the 2nd quarter worth approximately $30,000. Finally, Beaird Harris Wealth Management LLC grew its position in shares of CVS Health by 201.0% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 195 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Up 2.3%

Shares of CVS Health stock opened at $92.45 on Friday. The stock has a market capitalization of $118.25 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68. The stock has a 50 day moving average price of $91.80 and a two-hundred day moving average price of $93.03. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The company had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same period in the prior year, the firm earned $1.81 earnings per share. CVS Health’s revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd will be issued a dividend of $0.6650 per share. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health’s dividend payout ratio is presently 70.37%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Improving fundamentals and valuation support the stock. CVS has recently exceeded earnings and revenue expectations, while analysts cited stronger returns, rising earnings estimates and a lower valuation than Alignment Healthcare. Its Aetna turnaround is also viewed as a potential catalyst. CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?
• Positive Sentiment: Expanded care access and quality credentials reinforce CVS’s healthcare-services strategy. CVS opened its first pharmacy-focused location in the Boston area to improve access to medications, immunizations and other services. Separately, MinuteClinic received its seventh consecutive Joint Commission accreditation, with primary care available at more than 65% of its locations. CVS Pharmacy Celebrates Opening of First Pharmacy-Focused Location in Boston Area
• Neutral Sentiment: New women’s-health collaboration could support longer-term engagement. CVS is partnering with The Midlife Collective on a research study and documentary focused on women’s midlife health. The initiative may strengthen brand awareness and consumer relationships, but it is unlikely to have a near-term financial impact. CVS Health Collaborates With The Midlife Collective
• Positive Sentiment: Home-based heart monitoring expands value-added services. Signify Health, part of CVS, offers continuous heart-rhythm monitoring for eligible health-plan members, potentially enabling earlier detection of serious conditions and supporting preventive-care economics. CVS Health: Early Detection Matters
• Negative Sentiment: $315 million opioid settlement creates legal, financial and reputational pressure. CVS agreed to settle Justice Department allegations involving unlawful opioid dispensing and false claims. The company admitted no wrongdoing but will implement tighter controlled-substance oversight, adding costs and highlighting compliance risks. CVS Agrees to Pay $315M

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Robert W. Baird set a $107.00 target price on shares of CVS Health in a research report on Thursday, August 6th. Piper Sandler set a $112.00 target price on shares of CVS Health in a research note on Wednesday, September 9th. UBS Group restated a “buy” rating on shares of CVS Health in a report on Tuesday, September 22nd. JPMorgan Chase & Co. lifted their price target on shares of CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Argus upped their price objective on shares of CVS Health from $104.00 to $114.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $107.80.

CVS Health Company Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.